(MIST1)-Part 1: Assessment & Feasibility of Post-Symptoms Evaluation (MIST1)
Assessing New or Worsening Symptoms (Aka Adverse Events for This Study) After Chiropractic Care at a Chiropractic Teaching Clinic: An Active Surveillance Pilot Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Healthcare systems acknowledge the importance of patient safety including the reduction of preventable adverse events (AE). For healthcare providers who perform spinal manipulation therapy (SMT), the investigation of AEs remains in its infancy for several reasons including finding a reporting system that accurately collects AEs information, varied descriptions of AE's severity and occurrence frequency and the variable natural history of musculoskeletal conditions treated by SMT. Together, these factors act together to conspire against the implementation of systematic changes in SMT application that would result in improved patient care and safety.
In addition, it is vital that patient safety training initiates at the start of a healthcare worker's career. This pilot active surveillance study was designed to assess the feasibility of collecting data on patients' self-report of symptom changes as well as interns' report at a chiropractic teaching clinic.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients at the Parker University Wellness Clinic
- Agreed to participate
Exclusion Criteria:
- none
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Patient Encounters That Report a New or Worsening Symptom
Time Frame: Up to 7 days post treatment - Day 0-7
|
An adverse advent is any unfavorable sign, symptom or disease temporarily associated with the treatment, whether or not caused by the treatment, specifically any worsened or new symptom reported by the patient up to one week after care.
|
Up to 7 days post treatment - Day 0-7
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Katherine A Pohlman, DC, MS, PhD, Parker University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- Parker16_001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Patient Safety
-
NCT03728855TerminatedPatient Empowerment | Patient Safety | Medication Safety
-
NCT04990986CompletedPatient Safety | Medication Safety
-
NCT07584005CompletedNursing Education | Patient Safety | Medication Safety
-
NCT04897087Recruiting
-
NCT06738316Completed
-
NCT06574906Active, not recruiting
-
NCT05958108Active, not recruiting
-
NCT05530187RecruitingPatient Reported Outcome Measures | Patient Safety
-
NCT05062434Not yet recruiting
Clinical Trials on active surveillance
-
NCT02268331Completed
-
NCT05898347Enrolling by invitationBasal Cell Carcinoma | Gorlin Syndrome
-
NCT06394037Not yet recruitingActive Surveillance | Lung Ground-glass Opacities
-
NCT05940415Recruiting
-
NCT02971085Recruiting
-
NCT05953181Active, not recruitingEsophageal Cancer | Surgical Oncology | Neoadjuvant Chemoradiotherapy | Active Surveillance